Self-amplifying RNA COVID-19 vaccine
Copyright © 2024 Elsevier Inc. All rights reserved..
In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:187 |
|---|---|
| Enthalten in: |
Cell - 187(2024), 8 vom: 11. Apr., Seite 1822-1822.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wayne, Christopher J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARCT-154 vaccine |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 16.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cell.2024.03.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370979591 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370979591 | ||
| 003 | DE-627 | ||
| 005 | 20240417232951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cell.2024.03.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM370979591 | ||
| 035 | |a (NLM)38608649 | ||
| 035 | |a (PII)S0092-8674(24)00309-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wayne, Christopher J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Self-amplifying RNA COVID-19 vaccine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a ARCT-154 vaccine |2 NLM | |
| 700 | 1 | |a Blakney, Anna K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell |d 1974 |g 187(2024), 8 vom: 11. Apr., Seite 1822-1822.e1 |w (DE-627)NLM000088935 |x 1097-4172 |7 nnns |
| 773 | 1 | 8 | |g volume:187 |g year:2024 |g number:8 |g day:11 |g month:04 |g pages:1822-1822.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cell.2024.03.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 187 |j 2024 |e 8 |b 11 |c 04 |h 1822-1822.e1 | ||